Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol (2005) 4.40

Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer (2009) 1.89

Prostate cancers in men with low PSA levels--must we find them? N Engl J Med (2004) 1.52

Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol (2009) 1.49

Prostate cancer in young men: an important clinical entity. Nat Rev Urol (2014) 1.15

Prognostic factors for failure after prostatectomy. J Cancer (2010) 1.08

Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol (2012) 1.07

Progression after radical prostatectomy for men in their thirties compared to older men. BJU Int (2008) 1.00

Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res (2009) 0.96

Management of biochemical recurrence after primary localized therapy for prostate cancer. Front Oncol (2012) 0.90

Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol (2008) 0.87

Reconciling primary care and specialist perspectives on prostate cancer screening. Ann Fam Med (2012) 0.85

Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. J Urol (2008) 0.84

The dilemma of multiorgan donors with high serum PSA--a pathologist's proposal. Virchows Arch (2006) 0.83

A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer. Biomed Res Int (2014) 0.82

Biochemical recurrence-free and cancer-specific survival after radical prostatectomy at a single institution. Korean J Urol (2010) 0.82

Prostate cancer magnetic resonance imaging (MRI): multidisciplinary standpoint. Quant Imaging Med Surg (2013) 0.82

Prostate cancer in men aged less than 50 years at diagnosis. World J Urol (2016) 0.79

New techniques and management options for localized prostate cancer. Rev Urol (2006) 0.78

Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. Asian J Androl (2008) 0.77

The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years. Am J Clin Exp Urol (2014) 0.77

Younger patients have poorer biochemical outcome after radical prostatectomy in high-risk prostate cancer. Asian J Androl (2011) 0.76

Screening for prostate cancer: the debate continues. J Adv Pract Oncol (2013) 0.75

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11

Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02

NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98

Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49

Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol (2004) 4.41

Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24

African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology (2007) 4.02

Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68

Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32

Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29

Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25

An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21

Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14

ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol (2004) 3.08

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05

Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol (2009) 3.01

Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98

Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95

Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79

An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77

Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76

Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol (2002) 2.68

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68

Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67

Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol (2011) 2.65

PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63

Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61

Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54

Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol (2008) 2.51

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol (2009) 2.41

Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41

Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35

Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol (2006) 2.34

The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32

NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31

The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29

Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27

Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol (2011) 2.20

HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18

Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17

Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17